We are proud to announce the beginning of a new distribution agreement with Scintila S.R.O, who will be distributing our products across Czech Republic and Slovakia.
Our global customer base is growing rapidly due to problems associated with cryogenics, the vast increase in the use of complex physiologically relevant cell models in drug discovery, and our movement towards the regulated market of cell and gene therapy. Under this agreement, Scintila S.R.O, will increase our visibility and distribute Atelerix’s portfolio of hypothermic cell, tissue, and virus preservation technology.
Scintila, s.r.o. is a distribution company that has been focusing on long-term cooperation with top and renowned foreign manufacturers of products and technologies for biomedical research and diagnostics for almost 20 years.
They offer high-quality, innovative reagents and devices for research laboratories and clinical workplaces in the Czech Republic and Slovakia. With an important customer base consisting of key university hospitals, universities, academies of science and biotechnology companies.
Atelerix has been awarded a place on the Global Business Innovation Programme for Biomanufacturing of Biologics and Advanced Therapies in Canada. Organised by Innovate UK and delivered by Innovate UK EDGE, this programme, comprising workshops and a 5-day innovation visit to Canada, will support Atelerix’s future entry into the advanced therapies market.
“We are very pleased to be awarded a place on this programme. It will allow us to engage with advanced therapy developers in Canada to establish key pain points and confirm areas where Atelerix’s technology offers the greatest value. It will also foster key relationships, identifying collaborators and future partners, whilst gaining insight into the commercialisation and regulatory landscape in Canada.” Dr. Steve Swioklo
Atelerix sees global potential for the use of their hypothermic preservation technology in cell-based therapies and gene therapies after being demonstrated to dramatically extend the shelf life of leukapheresis starting material, therapeutic cell types, and viral vectors. The technology has also been successfully integrated into a clinical trial for an ocular cell-based therapy. It is hoped that this programme will offer an important contribution to Atelerix’s wider commercialisation within advanced therapies.
New White Paper Released! The sourcing of primary tissue is vital for many fields of research and is becoming increasingly important for use in advanced screening techniques/diagnosis, drug development and patient-derived model generation as healthcare moves towards personalised medicine. Tissue quality deteriorates rapidly after retrieval, and therefore need to be used as close to the retrieval time possible to ensure the best quality outcomes. Unfortunately, the sites of tissue retrieval is not always close to sites requiring the tissue, resulting in extended distribution times and a reduction in the quality of tissue.
TissueReady™ PLUS offers a simple solution that preserves the viability and quality of tissue at ambient temperatures, increasing their shelf-life, enabling shipment, enhancing the flexibility of workflows and improving the quality of screening and model generation from these tissues.
You can access the full paper using the link below:
TissueReady™ offers a simple solution that preserves the viability and quality of fresh tissue at ambient temperatures, increasing shelf life, enabling shipment, enhancing the flexibility of workflows and improving the quality of screening and model generation from these tissues.
Our newest release TissueReady™ PLUS now comes complete with recommended medium for the longest possible preservation times for fresh tissue samples. You can access the full launch webinar where Alistair Leitch, Senior R&D Manager talks through 3 external case studies using the link below:
